Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP732105.RAEC2_NECkCevxOT-EyCVJKhI2rBha6dfO35HbP9jOAis130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP732105.RAEC2_NECkCevxOT-EyCVJKhI2rBha6dfO35HbP9jOAis130_assertion type Assertion NP732105.RAEC2_NECkCevxOT-EyCVJKhI2rBha6dfO35HbP9jOAis130_head.
- NP732105.RAEC2_NECkCevxOT-EyCVJKhI2rBha6dfO35HbP9jOAis130_assertion wasGeneratedBy ECO_0000203 NP732105.RAEC2_NECkCevxOT-EyCVJKhI2rBha6dfO35HbP9jOAis130_provenance.
- NP732105.RAEC2_NECkCevxOT-EyCVJKhI2rBha6dfO35HbP9jOAis130_assertion wasDerivedFrom befree-2016 NP732105.RAEC2_NECkCevxOT-EyCVJKhI2rBha6dfO35HbP9jOAis130_provenance.
- NP732105.RAEC2_NECkCevxOT-EyCVJKhI2rBha6dfO35HbP9jOAis130_assertion SIO_000772 19363496 NP732105.RAEC2_NECkCevxOT-EyCVJKhI2rBha6dfO35HbP9jOAis130_provenance.
- NP732105.RAEC2_NECkCevxOT-EyCVJKhI2rBha6dfO35HbP9jOAis130_assertion evidence source_evidence_literature NP732105.RAEC2_NECkCevxOT-EyCVJKhI2rBha6dfO35HbP9jOAis130_provenance.
- NP732105.RAEC2_NECkCevxOT-EyCVJKhI2rBha6dfO35HbP9jOAis130_assertion description "[Our method can quantify amounts of MYC oncoprotein and B cell lymphoma protein-2 (BCL2) in Burkitt's and follicular lymphoma; identify changes in activation of extracellular signal-related kinases-1 (ERK1) and ERK2, mitogen-activated kinase-1 (MEK), signal transducer and activator of transcription protein-3 (STAT3) and STAT5, c-Jun N-terminal kinase (JNK) and caspase-3 in imatinib-treated chronic myelogeneous leukemia (CML) cells; measure an unanticipated change in the phosphorylation of an ERK2 isomer in individuals with CML who responded to imatinib; and detect a decrease in STAT3 and STAT5 phosphorylation in individuals with lymphoma who were treated with atorvastatin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP732105.RAEC2_NECkCevxOT-EyCVJKhI2rBha6dfO35HbP9jOAis130_provenance.